Spatially encoded biological assays

• US 10,308,982 B2
• Filed: 06/20/2016
• Issued: 06/04/2019
• Est. Priority Date: 04/05/2010
• Status: Active Grant

• Current Assignee: Prognosys Biosciences Inc.
• Original Assignee: Prognosys Biosciences Inc.
• Inventors: Chee, Mark S.
• Primary Examiner(s): Martinell, James
• Application Number:
  US15/187,661
• Publication Number:
  US 20160298180A1
• Time in Patent Office: 1,079 Days
• Field of Search: None
• CPC Class Codes: B01L 3/502715 characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
• CPC Class Codes: C12Q 1/6804 Nucleic acid analysis using immunogens immunoassay G01N33/53
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6834 Enzymatic or biochemical coupling of nucleic acids to a solid phase
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6841 In situ hybridisation
• CPC Class Codes: C12Q 1/6869 Methods for sequencing
• CPC Class Codes: C12Q 1/6874 involving nucleic acid arrays, e.g. sequencing by hybridisation
• CPC Class Codes: C12Q 2535/122 Massive parallel sequencing
• CPC Class Codes: C12Q 2543/10 the purpose being "in situ" analysis
• CPC Class Codes: C12Q 2563/179 the label being a nucleic acid
• CPC Class Codes: C12Q 2565/515 characterised by the interaction between or sequential use of two or more arrays
• CPC Class Codes: C40B 30/04 by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• CPC Class Codes: C40B 60/04 Integrated apparatus specially adapted for both screening libraries and identifying library members
• CPC Class Codes: G01N 2458/10 Oligonucleotides as tagging agents for labelling antibodies
• CPC Class Codes: G01N 33/5308 for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
• CPC Class Codes: G01N 33/543 with an insoluble carrier for immobilising immunochemicals
• CPC Class Codes: G01N 33/6845 Methods of identifying protein-protein interactions in protein mixtures

Abstract

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Claims

1. A method to determine a spatial pattern of abundance or activity or both of a biological target in a sample, comprising the following steps:

delivering encoded probes for a biological target to multiple sites in a sample affixed to a support, wherein each encoded probe comprises a probe region capable of interacting with the biological target and a coding tag comprising an oligonucleotide that identifies the location of the site to which the encoded probe is delivered;

allowing the encoded probes to interact with the biological target in the sample;

separating encoded probes that specifically interact with the biological target from encoded probes that do not specifically interact with the biological target;

determining all or a portion of the sequence of the coding tag oligonucleotide of an encoded probe that specifically interacts with the biological target, thereby identifying the location of the site in the sample at which the encoded probe and its specifically interacting biological target are located; and

associating the abundance or activity or both of the biological target to the locations of the multiple sites in the sample.

2. The method of claim 1, wherein the biological target comprises a nucleic acid and the encoded probes are oligonucleotides.

3. The method of claim 2, where there are two encoded probes for the nucleic acid target at each of the multiple sites in the sample.

4. The method of claim 1, wherein the biological target comprises a protein, and the probe regions of the encoding probes are proteins.

5. The method of claim 4, wherein the biological target comprises an enzyme.

6. The method of claim 1, wherein probe regions of the encoded probes comprise an antibody.

7. The method of claim 1, wherein the probe regions of the encoded probes comprise an aptamer.

8. The method of claim 1, wherein the probe regions of the encoded probes comprise a small molecule.

9. The method of claim 1, further comprising an amplification step between the separating step and the determining step.

10. The method of claim 1, wherein the determining step is performed by nucleic acid sequencing.

11. The method of claim 10, wherein the sequencing is high-throughput digital nucleic acid sequencing.

12. The method of claim 1, wherein multiple biological targets in the sample are assayed and the product of the multiple biological targets being assayed and the multiple sites in the sample is greater than 20, 50, 75, 100, 1,000, 10,000, 100,000, or 1,000,000.

13. The method of claim 1, wherein the sequence of at least one hundred thousand, at least five hundred thousand, or at least one million encoded probes are determined in parallel.

14. The method of claim 1, wherein software programmed hardware performs at least two steps of the delivering step, the separation step, the determining step and the associating step.

15. The method of claim 1, wherein the probe regions of the encoded probes are proteins and the separating step is accomplished by capturing encoded probes specifically bound to the biological target using an affinity capture agent.

16. The method of claim 1, wherein the probe regions of the encoded probes are nucleic acids and the separating step is accomplished by washing the sample.

17. A method to determine a spatial pattern of abundance or activity or both of a nucleic acid target in a sample, comprising the following steps:

delivering an oligonucleotide probe for a nucleic acid target to multiple sites in a sample affixed to a support;

allowing the oligonucleotide probe to hybridize with the nucleic acid target in the sample;

washing unhybridized oligonucleotide probe from the sample;

delivering one or more encoding agents to the multiple sites in the sample, wherein the one or more encoding agents delivered to each site comprise an oligonucleotide that identifies the location of the site in the sample;

coupling the one or more encoding agents and the oligonucleotide probe delivered to each site to form an encoded probe hybridized with the nucleic acid target at the site;

determining all or a portion of the sequence of the encoded probe hybridized with the nucleic acid target, thereby identifying the location of the site in the sample at which the encoded probe and its hybridized nucleic acid target are located; and

associating the abundance or activity or both of the nucleic acid target to the locations of the multiple sites in the sample.

18. The method of claim 17, wherein multiple nucleic acid targets in the sample are assayed and the product of the multiple nucleic acid targets being assayed and the multiple sites in the sample is greater than 20, 50, 75, 10,000, 100,000, or 1,000,000.

19. The method of claim 17, wherein the sequence of at least one hundred thousand or at least one million encoded probes are determined in parallel.

20. The method of claim 17, wherein two oligonucleotide probes are delivered for the nucleic acid target.

21. The method of claim 17, wherein the coupling step is performed by ligation.

22. The method of claim 17, wherein the coupling step is performed by extension followed by ligation.

23. The method of claim 17, further comprising an amplification step between the coupling step and the determining step.

24. A method to determine a spatial pattern of abundance or activity or both of a biological target in a sample, comprising the following steps:

delivering a probe for a biological target to multiple sites in a sample affixed to a support;

allowing the probe to interact with the biological target in the sample;

delivering an encoding agent to the multiple sites in the sample, wherein the encoding agent delivered to each site comprises an oligonucleotide that identifies the location of the site in the sample;

coupling the encoding agent and the probe delivered to each site to form an encoded probe interacting with the biological target at the site;

determining all or a portion of the sequence of the encoded probe interacting with the biological target, thereby identifying the location of the site in the sample at which the encoded probe and its interacting biological target are located;

associating the abundance or activity or both of the biological target to the locations of the multiple sites in the sample.

25. The method of claim 24, wherein one or more biological targets in the sample are assayed in parallel.

26. The method of claim 25, wherein for each biological target, one or more probes capable of specific binding to the biological target are delivered to the multiple sites in the sample.

27. The method of claim 24, wherein at least two encoding agents are delivered to each of the multiple sites in the sample and are coupled to the probe delivered to the site to form an encoded probe comprising the at least two encoding agents.

28. The method of claim 24, wherein the biological target comprises a nucleic acid and the probe is capable of specific hybridization with the nucleic acid of the biological target, wherein a sequence of the probe identifies the nucleic acid target.

29. The method of claim 24, wherein the biological target comprises a polypeptide and the probe comprises a polypeptide portion and a nucleic acid portion, wherein a sequence of the nucleic acid portion identifies the polypeptide portion.

30. The method of claim 24, wherein the biological target comprises an enzyme, and the probe comprises a substrate or putative substrate for the enzyme.

31. The method of claim 24, wherein the probe comprises an affinity capture agent, antibody, aptamer, or small molecule.

32. The method of claim 24, further comprising amplifying all or a portion of a sequence of the encoded probe.

33. The method of claim 24, wherein the determining step is performed by nucleic acid sequencing.

34. The method of claim 24, wherein multiple biological targets in the sample are assayed and the product of the multiple biological targets being assayed and the multiple sites in the sample is greater than 20, 50, 75, 100, 1,000, 10,000, 100,000, or 1,000,000.

35. The method of claim 24, wherein the sequences of at least one hundred thousand, at least five hundred thousand, or at least one million encoded probes are determined in parallel.

36. The method of claim 24, wherein the probe for the biological target is delivered to the multiple sites in the sample according to a known spatial pattern.

37. The method of claim 24, wherein the encoding agent is delivered to the multiple sites in the sample according to a known spatial pattern.

38. The method of claim 24, further comprising separating probes specifically bound to the biological target from probes not specifically bound to the biological target.

39. The method of claim 24, wherein the coupling step is performed by ligation, or performed by extension followed by ligation.

40. The method of claim 24, wherein the encoded probe comprises one or more priming sites for amplification.

41. The method of claim 40, wherein the nucleic acid target comprises RNA.

42. The method of claim 24, wherein the encoded probe comprises one or more sequencing adapters.

43. The method of claim 24, wherein the biological target is a nucleic acid target, the probe is capable of hybridizing with the nucleic acid target, and the hybridized probe acts as a primer and is extended using the nucleic acid target as the template to form an extended probe.